Cowen and Co analyst Phil Nadeau is forecasting that peak Telaprevir sales could hit about $3 billion in the U. S and another $1 billion or so overseas. However, he noted that the estimate assumes Vertex will be able to expand the current HCV market since an estimated 75 percent of the 3.9 million Americans with HCV don't know they have it (BioWorld). The median price target by analysts for Vertex's stock is at $46.50, compared to its current share price of around $34, according to Thomson/First Call. 
Share:  <span class="sent">Cowen and Co analyst <span class="analyst">Phil Nadeau</span> is forecasting that peak Telaprevir sales could hit about $3 billion in the U. S and another $1 billion or so overseas.</span> However, he noted that the estimate assumes <span class="company">Vertex</span> will be able to expand the current HCV market since an estimated 75 percent of the 3.9 million Americans with HCV don't know they have it (BioWorld). The median price target by analysts for <span class="company">Vertex</span>'s stock is at $46.50, compared to its current share price of around $34, according to Thomson/First Call. Tweet this   read full story

Leerink Swann Research analyst Seamus Fernandez noted that although boceprevir did achieve a 75 percent SVR rate in one of its Phase II dosing regimens, he doubts the drug will be able to show superiority to telaprevir. Additionally, analysts estimated that just over half of the patients in Vertex's telaprevir trial achieved SVR after a 24 week drug regimen, while they expect boceprevir, like the current standard of care, to be part of a 48 week regimen. "While we believe boceprevir can capture 10 percent to 20 percent market share assuming comparable efficacy, telaprevir's seemingly manageable . safety profile suggests that boceprevir will have a tough time delivering a better outcome that would drive upgrades to our peak sales forecast of $500 million," Fernandez wrote in a research note. Meanwhile, Cowen and Co analyst Phil Nadeau is modeling peak telaprevir sales of about $3 billion in the U. S and another $1 billion or so overseas. 
Share:  Leerink Swann Research analyst Seamus Fernandez noted that although boceprevir did achieve a 75 percent SVR rate in one of its Phase II dosing regimens, he doubts the drug will be able to show superiority to telaprevir. Additionally, analysts estimated that just over half of the patients in <span class="company">Vertex</span>'s telaprevir trial achieved SVR after a 24 week drug regimen, while they expect boceprevir, like the current standard of care, to be part of a 48 week regimen. "While we believe boceprevir can capture 10 percent to 20 percent market share assuming comparable efficacy, telaprevir's seemingly manageable . safety profile suggests that boceprevir will have a tough time delivering a better outcome that would drive upgrades to our peak sales forecast of $500 million," Fernandez wrote in a research note.<span class="sent"> Meanwhile, Cowen and Co analyst <span class="analyst">Phil Nadeau</span> is modeling peak telaprevir sales of about $3 billion in the U. S and another $1 billion or so overseas.</span>...<span class="sent">Meanwhile, Cowen and Co analyst <span class="analyst">Phil Nadeau</span> is modeling peak telaprevir sales of about $3 billion in the U. S and another $1 billion or so overseas.</span> Yet he noted that the forecast assumes <span class="company">Vertex</span> will be able to expand the current HCV market. An estimated 75 percent of the 3.9 million Americans with HCV don't know they have it. Kauffman explained that's partially because of a lack of screening and partially because patients may not see much incentive to get diagnosed and treated if the existing drugs have harsh side effects and less than a 50 percent chance of curing them anyway. A drug that offers a better chance of cure, potentially in a shorter period of time, could motivate more patients to get treated. Tweet this   read full story